R1 Therapeutics

Transforming The Future Of Kidney Care

Redwood City, United States · Founded 2025 · $77.5M raised

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$77.5M
Last Round
$77.5M Series AMar 2026
Rounds
1

About

R1 Therapeutics is a clinical-stage biotechnology company developing innovative first-in-class therapies for patients with kidney disease. Its lead asset, AP306, is a pan phosphate transporter inhibitor targeting hyperphosphatemia in chronic kidney disease patients on dialysis, with a novel mechanism of action blocking three key phosphate transporters in the gut. The company launched in March 2026 with an oversubscribed $77.5 million Series A co-led by Abingworth, F-Prime, and DaVita Venture Group, and has operations in California, North Carolina, and Boston.

Summary

R1 Therapeutics is a Biotech company based in Redwood City, United States, founded in 2025. It has raised $77.5M in total across 1 round, most recently a $77.5M Series A round in Mar 2026. Investors include Abingworth Bioventures, DaVita Venture Group and F-Prime Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2026
$77.5M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

R1 Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/r1-therapeutics"><img src="https://indexed.vc/api/badge/company/r1-therapeutics" alt="R1 Therapeutics on Indexed.vc" width="260" height="76" /></a>